DDInter602 DDInter899
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Dronedarone {u} (Compound) resembles {v} (Compound) Ibutilide
Dronedarone {u} (Compound) binds {v} (Gene) CACNA1F
Dronedarone {u} (Compound) causes {v} (Side Effect) Skin disorder
Dronedarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Dronedarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Dronedarone {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Dronedarone {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Dronedarone (Compound) resembles Ibutilide (Compound)
Dronedarone (Compound) binds CACNA1F (Gene)
Dronedarone (Compound) causes Skin disorder (Side Effect)
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Dronedarone may lead to a major life threatening interaction when taken with Sorafenib